Q3014 HCPCS Level II code: Telehealth originating site facility fee
Q3014 is the HCPCS code for “Telehealth originating site facility fee” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q3014Telehealth originating site facility fee
Short description: Telehealth facility fee
HCPCS · United States
Medicare details
The indicators CMS publishes with Q3014 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Statute
- Type of service
- Other medical items or services
- BETOS category
- Other - Non-Medicare fee schedule
- Added
- Oct 1, 2001
Where Q3014 sits
- 1Q codesTemporary codes
- 2Active code Q3014Telehealth originating site facility fee
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q3014 mean?
Q3014 is the HCPCS code for “Telehealth originating site facility fee” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q3014?
CMS lists Q3014’s Medicare coverage as “Carrier judgment” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q3014
All Q codesQ2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per…Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures…Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic doseQ2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusionQ3001Radioelements for brachytherapy, any type, eachQ3027Injection, interferon beta-1a, 1 mcg for intramuscular useQ3028Injection, interferon beta-1a, 1 mcg for subcutaneous useQ3031Collagen skin testQ4001Casting supplies, body cast adult, with or without head, plasterQ4002Cast supplies, body cast adult, with or without head, fiberglassQ4003Cast supplies, shoulder cast, adult (11 years +), plaster